{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:46Z","timestamp":1788306766766,"version":"build-2803163510"},"reference-count":180,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Ulcerative colitis (UC), a subtype of inflammatory bowel disease (IBD), is a chronic, relapsing inflammatory condition that significantly impairs the patient\u2019s quality of life. While biologics have transformed disease management, a substantial number of patients remain unresponsive or lose efficacy over time. Tofacitinib (TOFA), an oral Janus kinase (JAK) inhibitor, introduces a novel therapeutic class of small-molecule drugs with a unique oral administration route, offering enhanced patient convenience and broader accessibility compared to parenterally administered biologics. As the first oral treatment approved for moderate to severe UC in years, TOFA acts by modulating the JAK\/STAT pathway, influencing critical inflammatory mediators such as IL-6, IL-17, and IFN-\u03b3. However, response rates are variable and appear dose-dependent, with up to 60% of patients showing inadequate therapeutic outcomes. This review represents the first comprehensive synthesis focused specifically on biomarkers of TOFA response in UC. Drawing on multi-omics data\u2014epigenomics, transcriptomics, proteomics, and cellular profiling, we highlight emerging predictors of responsiveness, including CpG methylation signatures (e.g., LRPAP1 and FGFR2), transcriptomic regulators (e.g., REG3A and CLDN3), immune and epithelial cell shifts, and the cationic transporter MATE1. TOFA demonstrates a dual mechanism by modulating immune responses while supporting epithelial barrier restoration. Despite being promising, TOFA\u2019s dose-dependent efficacy and interpatient variability underscore the critical need for non-invasive, predictive biomarkers to guide personalized treatment. As the first review of its kind, this work establishes a basis for precision medicine approaches to optimize the clinical utility of TOFA in UC management.<\/jats:p>","DOI":"10.3390\/genes16080908","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T07:37:23Z","timestamp":1753861043000},"page":"908","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"16","author":[{"given":"Anja","family":"Bizjak","sequence":"first","affiliation":[{"name":"Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2461-6729","authenticated-orcid":false,"given":"Boris","family":"Gole","sequence":"additional","affiliation":[{"name":"Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-5345","authenticated-orcid":false,"given":"Gregor","family":"Jezernik","sequence":"additional","affiliation":[{"name":"Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-9428","authenticated-orcid":false,"given":"Uro\u0161","family":"Poto\u010dnik","sequence":"additional","affiliation":[{"name":"Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-9683","authenticated-orcid":false,"given":"Mario","family":"Gorenjak","sequence":"additional","affiliation":[{"name":"Centre for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.12998\/wjcc.v8.i6.1013","article-title":"Microbiota-gut-brain axis and its affect inflammatory bowel disease: Pathophysiological concepts and insights for clinicians","volume":"8","author":"Sinagra","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41586-020-2025-2","article-title":"Pathway paradigms revealed from the genetics of inflammatory bowel disease","volume":"578","author":"Graham","year":"2020","journal-title":"Nature"},{"key":"ref_3","unstructured":"McDowell, C., Farooq, U., and Haseeb, M. (2025). Inflammatory Bowel Disease. StatPearls, StatPearls Publishing LLC."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Greenwood-Van Meerveld, B. (2017). Inflammatory Bowel Disease: Pathophysiology and Current Therapeutic Approaches. Gastrointestinal Pharmacology, Springer International Publishing.","DOI":"10.1007\/978-3-319-56360-2"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/gut.32.8.913","article-title":"Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease","volume":"32","author":"Murch","year":"1991","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumour necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/0016-5085(94)90398-0","article-title":"Tumor necrosis factor \u03b1-producing cells in the intestinal mucosa of children with inflammatory bowel disease","volume":"106","author":"Breese","year":"1994","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1083\/jcb.200902153","article-title":"Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo","volume":"189","author":"Marchiando","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ruder, B., Atreya, R., and Becker, C. (2019). Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20081887"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0140-6736(93)91375-V","article-title":"Tumour-necrosis-factor antibody treatment in Crohn\u2019s disease","volume":"342","author":"Derkx","year":"1993","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/futurepharmacol4010017","article-title":"Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future","volume":"4","author":"Manrai","year":"2024","journal-title":"Future Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Schoultz, I., and Keita, \u00c5.V. (2019). Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function. Cells, 8.","DOI":"10.3390\/cells8020193"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2468-1253(18)30233-4","article-title":"Risankizumab in patients with moderate to severe Crohn\u2019s disease: An open-label extension study","volume":"3","author":"Feagan","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"Kopylov","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.cgh.2010.04.021","article-title":"Certolizumab Pegol in Patients with Moderate to Severe Crohn\u2019s Disease and Secondary Failure to Infliximab","volume":"8","author":"Sandborn","year":"2010","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","first-page":"26","article-title":"Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice","volume":"10","author":"Farkas","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-to-Severe Ulcerative Colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ecco-jcc\/jjx176","article-title":"The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn\u2019s Disease","volume":"12","author":"Greener","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: Evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: Results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Long, D. (2024). Crohn\u2019s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 12.","DOI":"10.3390\/biomedicines12030689"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gorenjak, M., Gole, B., Gori\u010dan, L., Jezernik, G., Prosenc Zmrzljak, U., Pernat, C., Skok, P., and Poto\u010dnik, U. (2024). Single-Cell Transcriptomic and Targeted Genomic Profiling Adjusted for Inflammation and Therapy Bias Reveal CRTAM and PLCB1 as Novel Hub Genes for Anti-Tumor Necrosis Factor Alpha Therapy Response in Crohn\u2019s Disease. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16060835"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kimko, H.H.C., and Peck, C.C. (2011). Application of Modeling and Simulation in the Development of Protein Drugs. Clinical Trial Simulations: Applications and Trends, Springer.","DOI":"10.1007\/978-1-4419-7415-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.3748\/wjg.v20.i43.16014","article-title":"Risk of infections associated with biological treatment in inflammatory bowel disease","volume":"20","author":"Andersen","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.cgh.2024.03.042","article-title":"Ozanimod in Patients with Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies","volume":"22","author":"Sands","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2020.03.033","article-title":"Cost considerations for clinicians prescribing biologic drugs: Who pays?","volume":"146","author":"Hvisdas","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"100075","DOI":"10.1016\/j.medidd.2020.100075","article-title":"Biologics vs. small molecules: Drug costs and patient access","volume":"9","author":"Makurvet","year":"2021","journal-title":"Med. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","first-page":"e45416","article-title":"Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis","volume":"15","author":"Malakar","year":"2023","journal-title":"Cureus"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/366129a0","article-title":"The protein tyrosine kinase JAK1 complements defects in interferon-alpha\/beta and -gamma signal transduction","volume":"366","author":"Briscoe","year":"1993","journal-title":"Nature"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"25028","DOI":"10.1074\/jbc.270.42.25028","article-title":"A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells","volume":"270","author":"Lai","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_42","first-page":"2057","article-title":"Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase","volume":"11","author":"Wilks","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0092-8674(92)90105-L","article-title":"A protein tyrosine kinase in the interferon alpha\/beta signaling pathway","volume":"70","author":"Velazquez","year":"1992","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2014.05.011","article-title":"Update on Janus Kinase Antagonists in Inflammatory Bowel Disease","volume":"43","author":"Boland","year":"2014","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.cell.2020.04.052","article-title":"SnapShot: Jak-STAT Signaling II","volume":"181","author":"Villarino","year":"2020","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"496","DOI":"10.5312\/wjo.v5.i4.496","article-title":"Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry\/clinical perspectives","volume":"5","author":"Malemud","year":"2014","journal-title":"World J. Orthop."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_51","unstructured":"Pfizer Inc (2025, May 14). Pfizer Announces U.S. FDA Approves XELJANZ\u00ae (Tofacitinib) for the Treatment of Moderately to Severely Active Ulcerative Colitis. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_announces_u_s_fda_approves_xeljanz_tofacitinib_for_the_treatment_of_moderately_to_severely_active_ulcerative_colitis-0?utm_source=chatgpt.com."},{"key":"ref_52","unstructured":"Pfizer Inc (2025, May 14). XELJANZ\u00ae (Tofacitinib Citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0?utm_source=chatgpt.com."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107723","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/apt.16712","article-title":"Safety and efficacy of tofacitinib for treatment of ulcerative colitis: Final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment","volume":"55","author":"Sandborn","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.14309\/ajg.0000000000002761","article-title":"Effectiveness of Tofacitinib in Patients With Ulcerative Colitis: A Nationwide Veterans Administration Cohort Study","volume":"119","author":"Khan","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ecco-jcc\/jjad158","article-title":"Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis","volume":"18","author":"Viola","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5217\/ir.2023.00194","article-title":"Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study","volume":"22","author":"Shimizu","year":"2024","journal-title":"Intest. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17562848231154103","DOI":"10.1177\/17562848231154103","article-title":"Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: A KASID multicenter cohort study","volume":"16","author":"Shin","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5217\/ir.2020.00030","article-title":"Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis","volume":"19","author":"Shimizu","year":"2021","journal-title":"Intest. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"jjaf076","DOI":"10.1093\/ecco-jcc\/jjaf076","article-title":"Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients","volume":"19","author":"Veny","year":"2025","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ueg2.12584","article-title":"Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure","volume":"12","author":"Sands","year":"2024","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.14309\/01.ajg.0000705436.64452.7d","article-title":"S0847 Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies: An Update as of February 2020","volume":"115","author":"Mahadevan","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: Results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Sandborn","year":"2017","journal-title":"Gut"},{"key":"ref_65","first-page":"1428","article-title":"Heritability in inflammatory bowel disease: From the first twin study to genome-wide association studies","volume":"21","author":"Gordon","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Loddo, I., and Romano, C. (2015). Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00551"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"i132","DOI":"10.1093\/ecco-jcc\/jjac190.0100","article-title":"DOP60 Environmental risk factors for Inflammatory bowel disease: A large prospective case-control study in India","volume":"17","author":"Banerjee","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41586-022-05308-6","article-title":"Identification of environmental factors that promote intestinal inflammation","volume":"611","author":"Sanmarco","year":"2022","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/ecco-jcc\/jjy117","article-title":"Genome-Wide DNA Methylation in Treatment-Na\u00efve Ulcerative Colitis","volume":"12","author":"Taman","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Taman, H., Fenton, C.G., Anderssen, E., Florholmen, J., and Paulssen, R.H. (2021). DNA hypo-methylation facilitates anti-inflammatory responses in severe ulcerative colitis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248905"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjad129","article-title":"Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis","volume":"18","author":"Joustra","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1073\/pnas.052159099","article-title":"Requirement of Ca2+ and CaMKII for Stat1 Ser-727 phosphorylation in response to IFN-gamma","volume":"99","author":"Nair","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jcp.21014","article-title":"Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus","volume":"212","author":"Citores","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/omi.2016.0005","article-title":"A Prospective Pharmacogenomic Study of Crohn\u2019s Disease Patients during Routine Therapy with Anti-TNF-alpha Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability","volume":"20","author":"Dezelak","year":"2016","journal-title":"OMICS"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1055\/a-0981-6516","article-title":"Genetic prediction profile for adalimumab response in Slovenian Crohn\u2019s disease patients","volume":"57","author":"Gorenjak","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2217\/pgs.14.172","article-title":"Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn\u2019s disease patients","volume":"16","author":"Koder","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10528-016-9734-0","article-title":"Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn\u2019s Disease Patients","volume":"54","author":"Repnik","year":"2016","journal-title":"Biochem. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101447","DOI":"10.1016\/j.gendis.2024.101447","article-title":"Inflammatory transcriptomic signatures and cell type compositions in inflamed and non-inflamed colonic mucosa of ulcerative colitis","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ncrna.2025.03.002","article-title":"Long non-coding RNA ANRIL\/p65 negative feedback loop protects intestinal barrier function in inflammatory bowel disease","volume":"12","author":"Yu","year":"2025","journal-title":"Noncoding RNA Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ecco-jcc\/jjx139","article-title":"Transcriptomic Landscape of Treatment-Na\u00efve Ulcerative Colitis","volume":"12","author":"Taman","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"G439","DOI":"10.1152\/ajpgi.00104.2022","article-title":"DNA sensor-associated type I interferon signaling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids","volume":"323","author":"Flood","year":"2022","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ito, Y., Watanabe, D., Okamoto, N., Miyazaki, H., Tokunaga, E., Ku, Y., Ooi, M., Hoshi, N., Kohashi, M., and Kanzawa, M. (2025). Activated type 17 helper T cells affect tofacitinib treatment outcomes. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-87076-7"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1182\/blood-2012-09-378653","article-title":"Essentials of Th17 cell commitment and plasticity","volume":"121","author":"Muranski","year":"2013","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/mt.2015.97","article-title":"Macrophage-Derived IGF-1 Is a Potent Coordinator of Myogenesis and Inflammation in Regenerating Muscle","volume":"23","author":"Tidball","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/dmrr.2676","article-title":"Multiple functions of Maf in the regulation of cellular development and differentiation","volume":"31","author":"Zhang","year":"2015","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1038\/s41467-022-29098-7","article-title":"Cell-intrinsic Aryl Hydrocarbon Receptor signalling is required for the resolution of injury-induced colonic stem cells","volume":"13","author":"Shah","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/wound.2013.0461","article-title":"Regenerative Wound Healing: The Role of Interleukin-10","volume":"3","author":"King","year":"2014","journal-title":"Adv. Wound Care"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Gonneaud, A., Turgeon, N., Boisvert, F.-M., Boudreau, F., and Asselin, C. (2021). JAK-STAT Pathway Inhibition Partially Restores Intestinal Homeostasis in Hdac1- and Hdac2-Intestinal Epithelial Cell-Deficient Mice. Cells, 10.","DOI":"10.3390\/cells10020224"},{"key":"ref_90","first-page":"1453","article-title":"Tofacitinib uptake by patient-derived intestinal organoids predicts individual clinical responsiveness","volume":"167","author":"Jang","year":"2024","journal-title":"bioRxiv"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00535-023-02013-7","article-title":"Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis","volume":"58","author":"Parkes","year":"2023","journal-title":"J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sommer, K., Wiendl, M., M\u00fcller, T.M., Heidbreder, K., Voskens, C., Neurath, M.F., and Zundler, S. (2021). Intestinal Mucosal Wound Healing and Barrier Integrity in IBD-Crosstalk and Trafficking of Cellular Players. Front. Med., 8.","DOI":"10.3389\/fmed.2021.643973"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e8483","DOI":"10.15252\/emmm.201708483","article-title":"Human ALPI deficiency causes inflammatory bowel disease and highlights a key mechanism of gut homeostasis","volume":"10","author":"Parlato","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1126\/science.1127119","article-title":"Symbiotic bacteria direct expression of an intestinal bactericidal lectin","volume":"313","author":"Cash","year":"2006","journal-title":"Science"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.12998\/wjcc.v8.i24.6389","article-title":"Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report","volume":"8","author":"Komeda","year":"2020","journal-title":"World J. Clin. Cases"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00441-013-1592-z","article-title":"REG gene expression in inflamed and healthy colon mucosa explored by in situ hybridisation","volume":"352","author":"Brenna","year":"2013","journal-title":"Cell Tissue Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1073\/pnas.1009399107","article-title":"Claudin-4 forms paracellular chloride channel in the kidney and requires claudin-8 for tight junction localization","volume":"107","author":"Hou","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/nyas.13360","article-title":"Intestinal epithelial claudins: Expression and regulation in homeostasis and inflammation","volume":"1397","author":"Quiros","year":"2017","journal-title":"Ann. N Y Acad. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1478-811X-12-27","article-title":"Signaling by epithelial members of the CEACAM family\u2014Mucosal docking sites for pathogenic bacteria","volume":"12","author":"Tchoupa","year":"2014","journal-title":"Cell Commun. Signal."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2468-1253(24)00390-X","article-title":"The intestinal barrier: A pivotal role in health, inflammation, and cancer","volume":"10","author":"Neurath","year":"2025","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/(SICI)1096-9896(199610)180:2<146::AID-PATH643>3.0.CO;2-E","article-title":"Heterogeneous expression of carcinoembryonic antigen in the normal colon and upregulation in active ulcerative colitis","volume":"180","author":"Smithson","year":"1996","journal-title":"J. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI30504","article-title":"CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease","volume":"117","author":"Barnich","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Saiz-Gonzalo, G., Hanrahan, N., Rossini, V., Singh, R., Ahern, M., Kelleher, M., Hill, S., O\u2019Sullivan, R., Fanning, A., and Walsh, P.T. (2021). Regulation of CEACAM Family Members by IBD-Associated Triggers in Intestinal Epithelial Cells, Their Correlation to Inflammation and Relevance to IBD Pathogenesis. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.655960"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.mam.2012.11.004","article-title":"Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K","volume":"34","author":"Motohashi","year":"2013","journal-title":"Mol. Asp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1021\/acsmedchemlett.3c00266","article-title":"Platinum\u2013Acridine Agents with High Activity in Cancers Expressing the Solute Carrier MATE1 (SLC47A1)","volume":"14","author":"Zhang","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_106","first-page":"4021","article-title":"Targeting the multidrug and toxin extrusion 1 gene (SLC47A1) sensitizes glioma stem cells to temozolomide","volume":"13","author":"Batara","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.4049\/jimmunol.1801199","article-title":"FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK\/STAT3 Signaling Pathway","volume":"202","author":"Li","year":"2019","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Reid, K.M., and Brown, G.C. (2023). LRPAP1 is released from activated microglia and inhibits microglial phagocytosis and amyloid beta aggregation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1286474"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1152\/physrev.00013.2017","article-title":"Human Olfactory Receptors: Novel Cellular Functions Outside of the Nose","volume":"98","author":"Hatt","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Flegel, C., Manteniotis, S., Osthold, S., Hatt, H., and Gisselmann, G. (2013). Expression profile of ectopic olfactory receptors determined by deep sequencing. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055368"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e70430","DOI":"10.1111\/jcmm.70430","article-title":"Hsa_circ_0004662 Accelerates the Progression of Ulcerative Colitis via the microRNA-532\/HMGB3 Signalling Axis","volume":"29","author":"Qiu","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ibd\/izab188","article-title":"Circular RNA HECTD1 Mitigates Ulcerative Colitis by Promoting Enterocyte Autophagy Via miR-182-5p\/HuR Axis","volume":"28","author":"Xu","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Fasseu, M., Tr\u00e9ton, X., Guichard, C., Pedruzzi, E., Cazals-Hatem, D., Richard, C., Aparicio, T., Daniel, F., Soul\u00e9, J.C., and Moreau, R. (2010). Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013160"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1038\/emm.2015.21","article-title":"MiR-155 modulates the inflammatory phenotype of intestinal myofibroblasts by targeting SOCS1 in ulcerative colitis","volume":"47","author":"Pathak","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Viennois, E., Zhao, Y., Han, M.K., Xiao, B., Zhang, M., Prasad, M., Wang, L., and Merlin, D. (2017). Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02782-1"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Brusnic, O., Adrian, B., Sorin-Radu, F., Grama, B., Sofonea, F., Roman-Filip, C., Roman-Filip, I., Solomon, A., B\u00eersan, S., and Dura, H. (2024). Importance of Fecal Microbiota Transplantation and Molecular Regulation as Therapeutic Strategies in Inflammatory Bowel Diseases. Nutrients, 16.","DOI":"10.3390\/nu16244411"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MIB.0000000000000687","article-title":"Role of Altered Expression of miR-146a, miR-155, and miR-122 in Pediatric Patients with Inflammatory Bowel Disease","volume":"22","author":"Kocsis","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12014-019-9224-6","article-title":"Ulcerative colitis: Functional analysis of the in-depth proteome","volume":"16","author":"Schniers","year":"2019","journal-title":"Clin. Proteom."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1172\/JCI19836","article-title":"Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis","volume":"113","author":"Fuss","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 Is the Key Effector Th2 Cytokine in Ulcerative Colitis That Affects Epithelial Tight Junctions, Apoptosis, and Cell Restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"103017","DOI":"10.1016\/j.autrev.2021.103017","article-title":"The influence of cytokines on the complex pathology of ulcerative colitis","volume":"21","author":"Nakase","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Bogaert, S., Laukens, D., Peeters, H., Melis, L., Olievier, K., Boon, N., Verbruggen, G., Vandesompele, J., Elewaut, D., and De Vos, M. (2010). Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol., 11.","DOI":"10.1186\/1471-2172-11-61"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/ibd\/izad290","article-title":"Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients","volume":"30","author":"Lethen","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ibd\/izz213","article-title":"Tofacitinib Reprograms Human Monocytes of IBD Patients and Healthy Controls Toward a More Regulatory Phenotype","volume":"26","author":"Cordes","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.coph.2014.06.004","article-title":"Th17 plasticity: Pathophysiology and treatment of chronic inflammatory disorders","volume":"17","author":"Cosmi","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12026-025-09633-6","article-title":"MOSPD2 regulates the activation state of \u03b1L\u03b22 integrin to control monocyte migration: Applicability for treatment of chronic inflammatory diseases","volume":"73","author":"Salem","year":"2025","journal-title":"Immunol. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/ecco-jcc\/jjz115","article-title":"IL-12 and Mucosal CD14+ Monocyte-Like Cells Induce IL-8 in Colonic Memory CD4+ T Cells of Patients with Ulcerative Colitis but not Crohn\u2019s Disease","volume":"14","author":"Chapuy","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.12703\/P6-13","article-title":"The M1 and M2 paradigm of macrophage activation: Time for reassessment","volume":"6","author":"Martinez","year":"2014","journal-title":"F1000Prime Rep."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Sridhar, A., Bakke, I., Gopalakrishnan, S., Osoble, N.M.M., Hammarqvist, E.P., Pettersen, H.P.S., Sandvik, A.K., \u00d8stvik, A.E., Hansen, M.D., and Bruland, T. (2025). Tofacitinib and budesonide treatment affect stemness and chemokine release in IBD patient-derived colonoids. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-86314-2"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1016\/j.apsb.2024.05.027","article-title":"Aloe emodin promotes mucosal healing by modifying the differentiation fate of enteroendocrine cells via regulating cellular free fatty acid sensitivity","volume":"14","author":"Bao","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.3748\/wjg.v29.i16.2380","article-title":"Molecular regulation mechanism of intestinal stem cells in mucosal injury and repair in ulcerative colitis","volume":"29","author":"Zheng","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.4049\/jimmunol.2200229","article-title":"RNF186\/EPHB2 Axis Is Essential in Regulating TNF Signaling for Colorectal Tumorigenesis in Colorectal Epithelial Cells","volume":"209","author":"Zhang","year":"2022","journal-title":"J. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s13287-021-02232-w","article-title":"Extracellular vesicles derived from EphB2-overexpressing bone marrow mesenchymal stem cells ameliorate DSS-induced colitis by modulating immune balance","volume":"12","author":"Yu","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"G396","DOI":"10.1152\/ajpgi.00383.2020","article-title":"Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1\/3 reduction in T-cells","volume":"320","author":"Brand","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"15899","DOI":"10.3748\/wjg.v20.i42.15899","article-title":"Interleukin-17 SNPs and serum levels increase ulcerative colitis risk: A meta-analysis","volume":"20","author":"Li","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Krawiec, P., and Pac-Ko\u017cuchowska, E. (2020). Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-69567-x"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2249.2006.03214.x","article-title":"Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice","volume":"146","author":"Ito","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Alhendi, A., and Naser, S.A. (2023). The dual role of interleukin-6 in Crohn\u2019s disease pathophysiology. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295230"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjac190.0045","article-title":"DOP05 Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients","volume":"17","author":"Veny","year":"2023","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature05698","article-title":"Epithelial NEMO links innate immunity to chronic intestinal inflammation","volume":"446","author":"Nenci","year":"2007","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1038\/s41467-025-57211-z","article-title":"Cooperation of TRADD- and RIPK1-dependent cell death pathways in maintaining intestinal homeostasis","volume":"16","author":"Sun","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Zan, G.X., Qu, H.Z., Li, X.Y., Peng, Q.L., Wang, X.F., Li, R.S., Zhao, Y.G., Yan, H.C., Zhou, J.Y., and Wang, X.Q. (2025). Iturin A Potentiates Differentiation of Intestinal Epithelial Defense Cells by Modulating Keap1\/Nrf2 Signaling to Mitigate Oxidative Damage Induced by Heat-Stable Enterotoxin B. Antioxidants, 14.","DOI":"10.3390\/antiox14040478"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Adrados, B., Wculek, S.K., Fern\u00e1ndez-Bravo, S., Torres-Ruiz, R., Valle-Noguera, A., Gomez-S\u00e1nchez, M.J., Hern\u00e1ndez-Walias, J.C., Ferreira, F.M., Corraliza, A.M., and Sancho, D. (2023). Expression of HMGCS2 in intestinal epithelial cells is downregulated in inflammatory bowel disease associated with endoplasmic reticulum stress. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1185517"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/gut.2006.094375","article-title":"Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn\u2019s disease","volume":"56","author":"Zeissig","year":"2007","journal-title":"Gut"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.bbamcr.2015.12.017","article-title":"Glutamine transporters in mammalian cells and their functions in physiology and cancer","volume":"1863","author":"Bhutia","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA)\u2013Mol. Cell Res."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Tamulyt\u0117, R., Jankaityt\u0117, E., Toleikis, Z., Smirnovas, V., and Jankunec, M. (2023). Pro-inflammatory protein S100A9 alters membrane organization by dispersing ordered domains. Biochim. Biophys. Acta (BBA)\u2013Biomembr., 1865.","DOI":"10.1016\/j.bbamem.2022.184113"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Aggeletopoulou, I., Kalafateli, M., Tsounis, E.P., and Triantos, C. (2024). Exploring the role of IL-1\u03b2 in inflammatory bowel disease pathogenesis. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1307394"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Mizoguchi, E., Sadanaga, T., Nanni, L., Wang, S., and Mizoguchi, A. (2024). Recently Updated Role of Chitinase 3-like 1 on Various Cell Types as a Major Influencer of Chronic Inflammation. Cells, 13.","DOI":"10.20944\/preprints202402.1627.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.7150\/thno.31073","article-title":"Hyaluronic Acid Oligosaccharides Improve Myocardial Function Reconstruction and Angiogenesis against Myocardial Infarction by Regulation of Macrophages","volume":"9","author":"Wang","year":"2019","journal-title":"Theranostics"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1753425916681077","article-title":"Inflammatory signaling pathways induced by Helicobacter pylori in primary human gastric epithelial cells","volume":"23","author":"Tran","year":"2017","journal-title":"Innate Immun."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Lee, H.-L., Tsai, Y.-C., Pikatan, N.W., Yeh, C.-T., Yadav, V.K., Chen, M.-Y., and Tsai, J.-T. (2023). Tumor-Associated Macrophages Affect the Tumor Microenvironment and Radioresistance via the Upregulation of CXCL6\/CXCR2 in Hepatocellular Carcinoma. Biomedicines, 11.","DOI":"10.3390\/biomedicines11072081"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/15384047.2020.1842705","article-title":"CXCL6 regulates cell permeability, proliferation, and apoptosis after ischemia-reperfusion injury by modulating Sirt3 expression via AKT\/FOXO3a activation","volume":"22","author":"Wang","year":"2021","journal-title":"Cancer Biol. Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1186\/s13287-021-02481-9","article-title":"Extracellular vesicles derived from mesenchymal stromal cells mediate endogenous cell growth and migration via the CXCL5 and CXCL6\/CXCR2 axes and repair menisci","volume":"12","author":"Kawata","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"ref_154","first-page":"CD008655","article-title":"The impact of biological interventions for ulcerative colitis on health-related quality of life","volume":"2015","author":"LeBlanc","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1111\/apt.15005","article-title":"Systematic review with network meta-analysis: The impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life","volume":"48","author":"Paschos","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_156","first-page":"656","article-title":"Etiology and Management of Lack or Loss of Response to Anti-Tumor Necrosis Factor Therapy in Patients with Inflammatory Bowel Disease","volume":"15","author":"Fine","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_157","first-page":"760","article-title":"Loss of Response and Requirement of Infliximab Dose Intensification in Crohn\u2019s Disease: A Review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40780-024-00386-2","article-title":"Factors influencing the discontinuation of biologic therapies in patients with ulcerative colitis","volume":"10","author":"Fukuyama","year":"2024","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1208\/s12249-025-03048-0","article-title":"Hansen Solubility Parameters, Computational, and Thermodynamic Models for Tofacitinib Citrate Solubility in Neat Mono Solvents, and GastroPlus Based Predicted In Vivo Performance of Subcutaneous Solution in Humans","volume":"26","author":"Ehsan","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Bhalani, D.V., Nutan, B., Kumar, A., and Singh Chandel, A.K. (2022). Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092055"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/ibd\/izad183","article-title":"Factors Associated with Response to Rescue Therapy in Acute Severe Ulcerative Colitis","volume":"30","author":"Seah","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jphp.12928","article-title":"Impact of gastrointestinal disease states on oral drug absorption\u2014Implications for formulation design\u2014A PEARRL review","volume":"71","author":"Effinger","year":"2019","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1124\/jpet.109.160804","article-title":"Genetic predictors of interindividual variability in hepatic CYP3A4 expression","volume":"332","author":"Lamba","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., and He, L. (2021). Cytochrome P450 Enzymes and Drug Metabolism in Humans. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312808"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Gouju, J., and Legeay, S. (2023). Pharmacokinetics of obese adults: Not only an increase in weight. Biomed. Pharmacother., 166.","DOI":"10.1016\/j.biopha.2023.115281"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1208\/s12248-025-01057-2","article-title":"Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects","volume":"27","author":"Sagawa","year":"2025","journal-title":"AAPS J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1093\/infdis\/jiae396","article-title":"MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor-\u03baB Signaling Pathway","volume":"231","author":"Kobeissy","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.cgh.2024.06.048","article-title":"AGA Clinical Practice Update on Endoscopic Scoring Systems in Inflammatory Bowel Disease: Commentary","volume":"22","author":"Buchner","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2499961","DOI":"10.1080\/07853890.2025.2499961","article-title":"Role of endoscopic ultrasound as a predictor of histological healing in ulcerative colitis","volume":"57","author":"Tian","year":"2025","journal-title":"Ann. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","article-title":"A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?","volume":"146","author":"Salmena","year":"2011","journal-title":"Cell"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Ye, Y., Zhang, L., Hu, T., Yin, J., Xu, L., Pang, Z., and Chen, W. (2021). CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn\u2019s disease. Sci. Rep., 11.","DOI":"10.1038\/s41598-020-80663-w"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Nie, J., and Zhao, Q. (2020). Lnc-ITSN1-2, Derived From RNA Sequencing, Correlates with Increased Disease Risk, Activity and Promotes CD4(+) T Cell Activation, Proliferation and Th1\/Th17 Cell Differentiation by Serving as a ceRNA for IL-23R via Sponging miR-125a in Inflammatory Bowel Disease. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00852"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41576-023-00662-1","article-title":"Non-coding RNAs in disease: From mechanisms to therapeutics","volume":"25","author":"Nemeth","year":"2024","journal-title":"Nat. Rev. Genet."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"6680526","DOI":"10.1155\/carm\/6680526","article-title":"A Not-So-Sweet Crohn\u2019s Disease: A Case Report of Ileocecal Crohn\u2019s Disease Unmasked by Sweet Syndrome","volume":"2025","author":"Omar","year":"2025","journal-title":"Case Rep. Med."},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Lang, F., Li, Y., Yao, R., and Jiang, M. (2025). Osteopontin in Chronic Inflammatory Diseases: Mechanisms, Biomarker Potential, and Therapeutic Strategies. Biology, 14.","DOI":"10.3390\/biology14040428"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"S, D.S.N., and Sundararajan, V. (2025). Gene expression analysis reveals mir-29 as a linker regulatory molecule among rheumatoid arthritis, inflammatory bowel disease, and dementia: Insights from systems biology approach. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0316584"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Gole, B., and Poto\u010dnik, U. (2019). Pre-Treatment Biomarkers of Anti-Tumour Necrosis Factor Therapy Response in Crohn\u2019s Disease\u2014A Systematic Review and Gene Ontology Analysis. Cells, 8.","DOI":"10.3390\/cells8060515"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Gorenjak, M., Zupin, M., Jezernik, G., Skok, P., and Poto\u010dnik, U. (2021). Omics data integration identifies ELOVL7 and MMD gene regions as novel loci for adalimumab response in patients with Crohn\u2019s disease. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84909-z"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/8\/908\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:18:23Z","timestamp":1760033903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/8\/908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":180,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["genes16080908"],"URL":"https:\/\/doi.org\/10.3390\/genes16080908","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]}}}